Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.
Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start clinical testing in lymphoma patients later this year.
AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgk